Sermorelin vs CJC-1295: Half-Life and Efficacy Comparison
Research Use Only. This article is for scientific and educational reference only. All products are sold for research purposes and are not intended for human or animal consumption.
# Sermorelin vs CJC-1295: Half-Life and Efficacy Comparison
For Research Purposes Only — Not Intended for Human or Animal Consumption
Introduction
Sermorelin and CJC-1295 are both synthetic analogues of growth hormone-releasing hormone (GHRH) that stimulate GH secretion by activating the GHRH receptor (GHRHR) on pituitary somatotrophs. They share the same mechanism of action but differ fundamentally in their pharmacokinetic profiles — a difference that has significant implications for research applications.
Sermorelin: The First GHRH Analogue
Sermorelin (GHRH 1-29 NH2) is a synthetic peptide corresponding to the first 29 amino acids of endogenous GHRH, which has 44 amino acids. The 1-29 fragment retains full GHRHR binding and activation activity — the C-terminal portion of GHRH (amino acids 30-44) is not required for receptor activation.
Sermorelin was FDA-approved (as Geref) for the treatment of GH deficiency in children and for the diagnosis of GH secretory capacity. It was withdrawn from the US market in 2008 for commercial reasons unrelated to safety or efficacy.
Pharmacokinetics: Sermorelin has a very short half-life of approximately 10-20 minutes in circulation. This rapid degradation is due to cleavage by dipeptidyl peptidase IV (DPP-IV) and other serum proteases. The short half-life means that Sermorelin produces a brief GH pulse following injection, mimicking the physiological GHRH pulse pattern.
CJC-1295: Extended Half-Life Through Structural Modification
CJC-1295 was developed to overcome Sermorelin's short half-life through two structural modifications:
D-Ala substitution at position 2: Replacement of the natural L-Ala at position 2 with D-Ala confers resistance to DPP-IV cleavage, the primary degradation pathway for GHRH analogues. This modification alone extends the half-life from ~10 minutes to approximately 30 minutes.
Drug Affinity Complex (DAC) technology: The version of CJC-1295 most commonly studied (CJC-1295 with DAC) incorporates a lysine residue modified with a maleimidoproprionic acid (MPA) linker that covalently binds to serum albumin after injection. Albumin binding dramatically extends the half-life to approximately 6-8 days.
The albumin-bound CJC-1295 acts as a depot, slowly releasing active peptide and providing sustained GHRHR stimulation over the entire inter-dose interval.
Pharmacokinetic Comparison
| Parameter | Sermorelin | CJC-1295 (no DAC) | CJC-1295 (with DAC) | |-----------|-----------|-------------------|---------------------| | Half-life | ~10-20 min | ~30 min | ~6-8 days | | Dosing frequency | 1-3x daily | 1-2x daily | Weekly or biweekly | | GH release pattern | Pulsatile | Semi-pulsatile | Sustained | | IGF-1 elevation | Modest | Moderate | Sustained, significant |
Clinical Evidence
Sermorelin: Multiple clinical trials demonstrated that daily Sermorelin injections increased GH secretion and IGF-1 levels in GH-deficient adults and children. The short half-life means that Sermorelin's effects are confined to the hours immediately following injection.
CJC-1295: Teichman et al. (2006) demonstrated that a single injection of CJC-1295 with DAC (at doses of 30-120 mcg/kg) produced GH increases that peaked at 2-6 hours post-injection and remained elevated for 6 days. IGF-1 levels increased 28-43% above baseline and remained elevated for 14 days after a single injection.
Research Application Implications
The pharmacokinetic differences between Sermorelin and CJC-1295 have important implications for research design:
For studies requiring pulsatile GH stimulation: Sermorelin's short half-life produces a discrete GH pulse, making it more appropriate for studies examining the pulsatile nature of GH secretion or for protocols designed to mimic physiological GH release patterns.
For studies requiring sustained GH/IGF-1 elevation: CJC-1295 with DAC provides sustained GH axis stimulation with infrequent dosing, making it more practical for longer-term studies examining the effects of sustained GH/IGF-1 elevation on body composition, bone density, or other endpoints.
For combination with GHRPs: Both compounds synergize with GHRPs (Ipamorelin, GHRP-6) to produce greater GH release than either compound alone. CJC-1295 is more commonly used in combination protocols due to its longer half-life.
References
- Teichman, S.L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.
- Walker, R.F. (2006). Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 1(4), 307–308.
- Ionescu, M., & Frohman, L.A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797.